|Bid||226.02 x 900|
|Ask||226.36 x 900|
|Day's range||217.87 - 233.30|
|52-week range||6.77 - 331.68|
|Beta (5Y monthly)||1.58|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Johnson & Johnson and Novavax are approaching the finish line in this race. A U.S. Food and Drug Administration (FDA) committee meets today, Feb. 26, to discuss a possible Emergency Use Authorization (EUA) for the Johnson & Johnson candidate. A trial report released this week shows Johnson & Johnson's investigational vaccine fulfilled (and exceeded) efficacy and safety requirements.
Novavax (NASDAQ: NVAX) is one stock that I made the right call on; it's been a huge winner. As far back as March 2018, I wrote that "if you're willing to take on risk, buying a small position in Novavax could pay off in a big way." Throughout 2020, I sang Novavax's praises.
Novavax doesn't have products on the market yet, which means the biotech company is yet to report an annual profit. Novavax recently reported U.K. phase 3 trial results and just completed enrollment in a U.S. phase 3 trial. Possible regulatory authorizations sit on the horizon.